Inventor · disambiguated record
Valeria G. Nicolini
Also filed as: NICOLINI VALERIA · NICOLINI VALERIA G
17 granted patents·18 pending applications·224 citations·filing 2011–2024
94Inventor score
Files withHOFFMANN LA ROCHE19ROCHE GLYCART AG13BACAC MARINA1FREIMOSER-GRUNDSCHOBER ANNE1GERDES CHRISTIAN1
Top patents by PatentIndex Score
35 records- 0198US10184009B2Mutant interleukin-2 polypeptidesROCHE GLYCART AG·Filed 2017·Granted Jan 22, 2019·37 cites·30 claims
- 0297US10577429B2Anti-FAP antibodies and methods of useROCHE GLYCART AG·Filed 2015·Granted Mar 3, 2020·17 cites·28 claims
- 0397US10323098B2Mutant interleukin-2 polypeptidesROCHE GLYCART AG·Filed 2016·Granted Jun 18, 2019·25 cites·30 claims
- 0497US10253110B2Anti-FAP antibodies and methods of useROCHE GLYCART AG·Filed 2015·Granted Apr 9, 2019·15 cites·17 claims
- 0596US11111312B2Mutant interleukin-2 polypeptidesROCHE GLYCART AG·Filed 2018·Granted Sep 7, 2021·8 cites·5 claims
- 0696US9526797B2Combination IL-2 immunoconjugate therapyROCHE GLYCART AG·Filed 2013·Granted Dec 27, 2016·57 cites·20 claims
- 0794US11332545B2Anti-FAP antibodies and methods of useROCHE GLYCART AG·Filed 2019·Granted May 17, 2022·6 cites·9 claims
- 0894US9011847B2Anti-FAP antibodies and methods of useBACAC MARINA·Filed 2011·Granted Apr 21, 2015·34 cites·26 claims
- 0993US11591397B2Bispecific antibody molecules binding to CD3 and EGFRvIIIHOFFMANN LA ROCHE·Filed 2021·Granted Feb 28, 2023·2 cites·15 claims
- 1093US10603360B2Combination IL-2 immunoconjugate therapyROCHE GLYCART AG·Filed 2016·Granted Mar 31, 2020·13 cites·22 claims
- 1191US12023368B2ImmunoconjugatesHOFFMANN LA ROCHE·Filed 2022·Granted Jul 2, 2024·1 cites·20 claims
- 1288US11413331B2ImmunoconjugatesHOFFMANN LA ROCHE·Filed 2018·Granted Aug 16, 2022·4 cites·30 claims
- 1386US11672858B2Bispecific antibody molecules binding to CD3 and TYRP-1HOFFMANN LA ROCHE·Filed 2019·Granted Jun 13, 2023·2 cites·16 claims
- 1485US11865082B2Combination therapy of PD-1-targeted IL-2 variant immunocytokines and antibodies against human PD-L1HOFFMANN LA ROCHE·Filed 2021·Granted Jan 9, 2024·1 cites·21 claims
- 1584US12473373B2Bispecific antibody molecules binding to CD3 and EGFRvIIIHOFFMANN LA ROCHE·Filed 2023·Granted Nov 18, 2025·0 cites·30 claims
- 1683US12286486B2Anti-FAP antibodies and methods of useROCHE GLYCART AG·Filed 2022·Granted Apr 29, 2025·0 cites·17 claims
- 1780US2023277662A1Antibodies binding to cd3HOFFMANN LA ROCHE·Filed 2023·Application pending·0 cites
- 1876US2025073308A1ImmunoconjugatesHOFFMANN LA ROCHE·Filed 2024·Application pending·0 cites
- 1973US9156913B2Anti-tenascin-C A2 antibodies and methods of useFREIMOSER-GRUNDSCHOBER ANNE·Filed 2011·Granted Oct 13, 2015·2 cites·18 claims
- 2071US2024216471A1Combination therapy of pd-1-targeted il-2 variant immunocytokines and antibodies against human pd-l1HOFFMANN LA ROCHE·Filed 2023·Application pending·0 cites
- 2169US2025101132A1Combination therapy of anti-tyrp1/anti-cd3 bispecific antibodies and tyrp1-specific antibodiesHOFFMANN LA ROCHE·Filed 2024·Application pending·0 cites
- 2266US2019322765A1Mutant interleukin-2 polypeptidesROCHE GLYCART AG·Filed 2019·Application pending·0 cites
- 2365US2024269277A1Alternative pd1-il7v immunoconjugates for the treatment of cancerHOFFMANN LA ROCHE·Filed 2024·Application pending·0 cites
- 2464US2020197492A1Combination il-2 immunoconjugate therapyROCHE GLYCART AG·Filed 2020·Application pending·0 cites
- 2564US2024425561A1New interleukin-7 immunoconjugatesHOFFMANN LA ROCHE·Filed 2024·Application pending·0 cites
- 2660US2014065097A1ImmunotherapyROCHE GLYCART AG·Filed 2013·Application pending·0 cites
- 2760US2019374609A1Combination therapy of tumor-targeted il-2 variant immunocytokines and antibodies against human pd-l1HOFFMANN LA ROCHE·Filed 2019·Application pending·0 cites
- 2859US2024262913A1Combination therapy of pd-1-targeted il-2 variant immunoconjugate and anti-tyrp1/anti-cd3 bispecific antibodiesHOFFMANN LA ROCHE·Filed 2022·Application pending·0 cites
- 2956US2024092856A1Combination therapy of pd-1-targeted il-2 variant immunoconjugates and fap/4-1bb binding moleculesHOFFMANN LA ROCHE·Filed 2022·Application pending·0 cites
- 3055US2012258073A1ImmunotherapyGERDES CHRISTIAN·Filed 2012·Application pending·0 cites
- 3155US2018200338A1Combination therapy of tumor-targeted il-2 variant immunocytokines and antibodies against human pd-l1HOFFMANN LA ROCHE·Filed 2017·Application pending·0 cites
- 3252US2016264651A1Anti-tenascin-c a2 antibodies and methods of useROCHE GLYCART AG·Filed 2015·Application pending·0 cites
- 3351US2023181712A1Combination therapy with modified pbmcs and an immunoconjugateHOFFMANN LA ROCHE·Filed 2021·Application pending·0 cites
- 3450US2020188526A1Interleukin-2 immunoconjugate, a cd40 agonist, and optionally a pd-1 axis binding antagonist for use in methods of treating cancerHOFFMANN LA ROCHE·Filed 2019·Application pending·0 cites
- 3549US2016175397A1Combination therapy of tumor-targeted il-2 variant immunocytokines and antibodies against human pd-l1HOFFMANN LA ROCHE·Filed 2015·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Valeria G. Nicolini files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →